Ribosome Biogenesis Serves as a Therapeutic Target for Treating Endometriosis and the Associated Complications

Area of Science:

• Cell Biology
• Reproductive Medicine
• Oncology

Background:

• Ribosome biogenesis is crucial for cell growth and protein homeostasis.
• Up-regulation of ribosome biogenesis is observed during endometriosis progression and malignant transition.
• Inhibiting ribosome biogenesis may offer a therapeutic strategy for endometriosis.

Purpose of the Study:

• To investigate the therapeutic potential of targeting ribosome biogenesis in endometriosis.
• To evaluate the efficacy of ribosome biogenesis inhibitors in a mouse model of endometriosis.

Main Methods:

• A mouse model mimicking human endometriosis features was established.
• Mice were treated with three drugs inhibiting ribosome biogenesis: GSK2126458 (mTOR/PI3K inhibitor), CX5461, and BMH21 (RNA polymerase I inhibitors).
• Lesion characteristics, immune cell populations (macrophages, neutrophils), and nerve fiber density were analyzed.

Main Results:

• Drug treatments significantly reduced average lesion numbers and disease frequencies compared to vehicle controls.
• Flow cytometry revealed decreased small peritoneal macrophages and neutrophils, with an increased ratio of large to small macrophages, indicating suppressed inflammation.
• Treated lesions exhibited lower nerve fiber density, correlating with observed pain relief in behavioral studies.

Conclusions:

• Ribosome biogenesis is a viable therapeutic target for endometriosis.
• Inhibiting ribosome biogenesis demonstrates efficacy in reducing endometriosis progression, inflammation, and associated pain.
• This study provides a strong foundation for developing novel anti-ribosome biogenesis therapies for endometriosis.